CMND (Clearmind Medicine Inc. Common Shares) stock: $0.78, $1.7M market cap, $3.9M cash, -$2.2M EV, $0.1M fully diluted market cap. Next expected readout: Dec-26. Lead program: CMND-100 (Alcohol Use Disorder), Phase 1/2. Data from Fully Diluted's biotech stocks database.
Share price
$0.78
Market cap
$1.7M
Cash
$3.9M
Enterprise value
-$2.2M
Balance sheet
Cash
$3.9M
Debt
$0.0M
Net cash
$3.9M
Enterprise value
-$2.2M
Basic shares
0.2M shares
Fully diluted shares
0.2M shares
Fully diluted market cap
$0.1M
Cash per share
$24.50
Cash figures as of 2025-10-31. Database snapshot: 2026-09-22.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.